Bovine NK-lysin peptides exert potent antimicrobial activity against multidrug-resistant *Salmonella* outbreak isolates

Rohana P. Dassanayake1*, Briony M. Atkinson2, Adam S. Mullis3, Shollie M. Falkenberg1, Eric M. Nicholson4, Eduardo Casas1, Balaji Narasimhan3 & Shawn M. D. Bearson2*

Multidrug-resistant (MDR) *Salmonella* is a threat to public health. Non-antibiotic therapies could serve as important countermeasures to control MDR *Salmonella* outbreaks. In this study, antimicrobial activity of cationic α-helical bovine NK-lysin-derived antimicrobial peptides was evaluated against MDR *Salmonella* outbreak isolates. NK2A and NK2B strongly inhibited MDR *Salmonella* growth while NK1 and NK2C showed minimum-to-no growth inhibition. Scrambled-NK2A, which is devoid of α-helicity but has the same net positive charge as NK2A, also failed to inhibit bacterial growth. Incubation of negatively charged MDR *Salmonella* with NK2A showed increased Zeta potential, indicating bacterial-peptide electrostatic attraction. Confocal and transmission electron microscopy studies revealed NK2A-mediated damage to MDR *Salmonella* membranes. LPS inhibited NK2A-mediated growth suppression in a dose-dependent response, suggesting irreversible NK2A-LPS binding. LPS-NK2A binding and bacterial membrane disruption was also confirmed via electron microscopy using gold nanoparticle-NK2A conjugates. Finally, NK2A-loaded polyanhydride nanoparticles showed sustained peptide delivery and anti-bacterial activity. Together, these findings indicate that NK2A α-helicity and positive charge are prerequisites for antimicrobial activity and that MDR *Salmonella* killing is mediated by direct interaction of NK2A with LPS and the inner membrane, leading to bacterial membrane permeabilization. With further optimization using nano-carriers, NK2A has the potential to become a potent anti-MDR *Salmonella* agent.

*Salmonella* causes an estimated 1.3 million food-borne related illnesses annually,1, and the Centers for Disease Control and Prevention (CDC) has classified drug resistant *Salmonella* as a serious threat. Multidrug-resistant (resistant to ≥ 3 antimicrobial classes, MDR) *Salmonella* infections have been associated with the consumption of food animal products such as ground beef, chicken, shell eggs, turkey and pork. In 2011, an MDR *S. Heidelberg* outbreak associated with ground turkey caused 136 human illnesses, one death, and the recall of 36 million pounds of ground turkey. In 2015, a multistate outbreak of MDR serovar 1,4,[5],12:i- with resistance to ampicillin, streptomycin, sulfisoxazole, and tetracycline (R-type, ASSuT) was linked to the consumption of contaminated pork products, resulting in 188 human infections, 30 hospitalization, and the recall of 523,380 pounds of meat. Currently, thousands of MDR serovar 1,4,[5],12:i- sequences have been submitted to the NCBI Pathogens Detection database, with some isolates containing resistance genes for up to 13 antimicrobial classes including antibiotics of clinical importance for treatment of *Salmonella* infections (manuscript in preparation). Global health entities have issued a call to action to “improve strategies for reducing AMR” by developing novel non-antibiotic therapeutics against MDR *Salmonella* to enhance food safety and public health.

Antimicrobial peptides (AMPs), a diverse group of evolutionarily conserved molecules which are typically composed of 5–50 amino acids, could be an important component of such non-antibiotic therapeutics. AMPs feature a broad spectrum of antimicrobial activity and relatively low resistance development. They are produced...
**Table 1.** Sources and properties of MDR and non-MDR *Salmonella* isolates.

| *Salmonella* isolates                  | Source                                                                 |
|---------------------------------------|------------------------------------------------------------------------|
| SX238: MDR *Salmonella enterica* serovar 14,5,12:i:- strain USDA15WA-1  |
| Resistant to: ampicillin, streptomycin, sulfisoxazole, and tetracycline   | Originally isolated from a 2015 US. multi-state pork outbreak from pork products^6^ and sequenced^57^ |
| SX231: MDR *Salmonella enterica* serovar Typhimurium DT193 strain 1434  |
| Resistant to: ampicillin, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and tetracycline | Originally a cattle isolate^18^ |
| SB395: MDR *Salmonella enterica* serovar Heidelberg                       |
| Resistant to: ampicillin, gentamicin, streptomycin, and tetracycline      | Originally isolated from a 2011 ground turkey outbreak^6^ Current isolate was passaged through a turkey^26^ |
| SB377: *Salmonella enterica* serovar Typhimurium isolate UK-1 Resistant to: nalidixic acid (made Na^1+^ in the lab for isolation purposes) | Originally isolated from the spleen of a chick orally inoculated 3 days earlier with a highly virulent S. typhimurium isolate retrieved from an infected horse in 1991 Our isolate was passaged through a pig and isolated from the ileocecal lymph node^57^ |

by most living organisms as a component of their innate immune system and are effective against a broad range of pathogens such as bacteria, protozoa, and fungi^7,^9,^11^ Based on the amino acid composition and structure, AMPs can be divided into five subgroups: anionic peptides, linear cationic α-helical peptides, cationic peptides enriched for specific amino acids, anionic and cationic peptides that contain cysteine and form disulfide bonds, and anionic and cationic peptide fragments of larger proteins^7.^ In addition to antimicrobial activity, AMPs such as cathelicidin peptide LL-37 and chicken NK-lysin show immunomodulatory properties^12,^13^.

Bovine NK-lysins are cationic, amphipathic α-helical AMPs produced by T lymphocytes and natural killer (NK) cells that are similar to human granulysin and porcine NK-lysin and are effective against various microbes^14–^16^.

Amino acid sequence comparisons indicated that granulysin and NK-lysins are related to the saposin-like protein (SAPLIP) family of lipid-binding proteins in lysosomes^16,19,^20^.

Endsley et al^17^ identified two *Salmonella* nanoparticles and anti-MDR *Salmonella* isolates. Therefore, NK2A binding to both LPS and MDR isolates was assessed. NK2A was identified as the most effective peptide against MDR isolates. Therefore, NK2A binding to both LPS and MDR *Salmonella* was further evaluated. Furthermore, payload release kinetics of NK2A encapsulated polyanhydride nanoparticles and anti-MDR *Salmonella* activity of NK2A encapsulated nanoparticles were examined.

**Results**

**Antimicrobial activity of NK-lysin peptides against MDR and non-MDR *Salmonella* isolates.** The antimicrobial effectiveness of bovine NK-lysin-derived peptides was assessed against *Salmonella* I 4,5,12:i:- pork outbreak isolate USDA15WA-1 (SX238) and a non-MDR *Salmonella* isolate (SB377) which is known as universal killer (UK1) (Table 1) in LB broth medium. Four synthetic 30-mer peptides (i.e., NK1, NK2A, NK2B, and NK2C) corresponding to the functional region of bovine NK-lysin (helix-2-loop-helix-3) were tested in growth curve assays. As shown in Fig. 1a and Supplementary Fig. S1, NK1 did not show

Resistant to: ampicillin, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and tetracycline

Resistant to: ampicillin, gentamicin, streptomycin, and tetracycline

Resistant to: nalidixic acid (made Na^1+^ in the lab for isolation purposes)

Resistant to: ampicillin, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and tetracycline

Resistant to: ampicillin, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and tetracycline

Resistant to: ampicillin, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and tetracycline

Resistant to: ampicillin, gentamicin, streptomycin, and tetracycline

Resistant to: nalidixic acid (made Na^1+^ in the lab for isolation purposes)

Resistant to: ampicillin, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and tetracycline

Resistant to: ampicillin, gentamicin, streptomycin, and tetracycline

Resistant to: nalidixic acid (made Na^1+^ in the lab for isolation purposes)
any Salmonella SX238 and SB377 growth inhibition activity at the tested peptide concentrations (highest up to 20 µM, Fig. 1a). Although 10 µM and 20 µM NK2C initially inhibited Salmonella SX238 and SB377 growth, bacteria recovered and grew at approximately 7 h and 20 h, respectively (Fig. 1a). In contrast, both NK2A and NK2B were highly effective and completely inhibited growth of Salmonella SX238 and SB377 at ≥ 5 µM concentration (Fig. 1a). Since NK2A peptide had a higher antimicrobial activity than NK2B (growth inhibition at 2 µM NK2A concentration for up to 8 h), this bovine NK-lysin peptide was selected for further studies, and the SX238 isolate was chosen for further studies with NK2A. Bactericidal activity of NK2A during 3 h incubation was also tested in PBS and LB broth, and all three NK2A concentrations (2, 5, 20 µM) were highly effective against Salmonella SX238, with greater than 97% and 99% killing, respectively ($P = 1.000$) (Fig. 1b).

**CD spectroscopy of Sc-NK2A.** In this study, the secondary structure of scrambled NK2A (Sc-NK2A) in a bacterial membrane-mimicking environment was determined using CD spectroscopy. Previous CD spectral
profile analyses confirmed all four bovine NK-lysin peptides to have α-helical conformation when bound with liposomes\textsuperscript{15}. The amino acid sequence in NK2A was scrambled and chemically synthesized as a control peptide (Sc-NK2A). Sc-NK2A is predicted to have no α-helical structure but with the same net positive charge as original NK2A (net charge = +7.9). Both peptides in phosphate buffer (without liposomes) showed CD spectra indicative of random coil structures (Fig. 2a). NK2A peptide in liposomes showed a CD profile characteristic of predominantly α-helical structure (maximum near ~192 nm with double minima near ~208 nm and ~222 nm) (Fig. 2a). In contrast, Sc-NK2A did not show a CD profile indicative of an α-helical structure (Fig. 2a), suggesting that the rearrangement of amino acids resulted in elimination of secondary α-helical structure.

Cytotoxicity studies with NK-lysin peptides. To assess the toxicity of NK-lysin peptides, a hemolytic assay and a mouse study were performed. It has previously been reported that all four 30-mer NK-lysin-derived peptides have minimal cytotoxic effect against cattle RBCs\textsuperscript{24}. To determine whether Sc-NK2A has hemolytic activity, a hemoglobin release assay was performed with cattle RBCs. Both NK2A and Sc-NK2A at the tested concentrations (2–20 µM) showed <2% hemolytic activity with no significant differences observed between the two peptides \((P = 0.1650)\) (Fig. 2b). Mice intraperitoneally injected with 100 µg of NK-lysin peptides (NK1, NK2A, NK2B, NK2C, or Sc-NK2A) did not show signs of toxicity or death during the 2-week observation period. These findings suggest that NK-lysin peptides have minimal toxic effects to both bovine red blood cells and mice at the tested concentrations.

Antimicrobial activities of Sc‑NK2A peptide. Bacterial growth inhibition assays were performed with Salmonella isolate SX238 using both NK2A and Sc-NK2A peptides (Fig. 2c). NK2A completely inhibited growth of SX238 at \(10^{-5}\) CFU/ml (or \(10^{-6}\) CFU/cell) during a 24 h growth period, and partial growth inhibition was observed (up to 9 h) at \(10^{1}\) CFU/ml (or \(10^{2}\) CFU/cell). Sc-NK2A failed to inhibit bacterial growth even at the lowest bacterial concentration (\(10^{1}\) CFU/cell). Using additional MDR Salmonella outbreak isolates originating from cattle (SX320) and turkey (SB395) along with SX238 and SB377 at \(10^{5}\) CFU/ml, the antimicrobial activity of NK2A and Sc-NK2A was compared. NK2A inhibited the growth of the four Salmonella isolates at or above the 5 µM concentration, although three of the four isolates were sensitive to a final NK2A concentration of 3.5 µM (Fig. 3). However, even 20 µM Sc-NK2A failed to show Salmonella growth inhibition activity (Fig. 3).

Effect of NK2A on Zeta potentials of MDR Salmonella. Bacterial Zeta potential has recently been shown to serve as a proxy for membrane permeabilization\textsuperscript{35}. Accordingly, Zeta potential measurements of NK-lysin peptides and Salmonella were evaluated. Cationic NK-lysin peptides including Sc-NK2A showed positive Zeta potential values in the range of 16.3–24.8 mV (Table 2). In contrast, three MDR and one non-MDR isolates of all four Salmonella isolates with negative Zeta potential values, which is attributed to the anionic LPS-outer membrane (Table 3). bacterial Zeta potential changes following incubation with NK2A (2 µM for 20 min) were assessed. Alteration of Salmonella Zeta potentials was observed following incubation with NK2A; the negative Zeta potentials of all four Salmonella isolates changed to positive Zeta potential values (ranging from 6.1–16.0 mV) suggesting NK2A-LPS (Salmonella) and/or NK2A-cytoplasmic membrane binding (Table 3). MDR Salmonella isolate SB395 with 2 µM Sc-NK2A increased Zeta potential value (7.8 mV), indicating that Sc-NK2A also bound to Salmonella membranes (Table 3). However, as shown in Fig. 3, Sc-NK2A at 20 µM did not inhibit Salmonella growth, suggesting that the scrambled, non-pore forming peptide can associate closely with the cell surface to change the observed bacterial surface charge to positive, but the presence of the α-helical structure is critical for anti-bacterial activity.

Effects of NK2A on MDR Salmonella morphology. To morphologically evaluate the dead MDR Salmonella SX238 following incubation with NK2A, confocal laser scanning microscopy (CLSM) and transmission electron microscopy (TEM) studies were performed. The LIVE/DEAD (BacLight) bacterial viability staining method was used to differentiate live (stained with SYTO 9, green) from dead (stained with propidium iodide (PI), red) bacteria. Primarily SYTO 9-stained bacteria (green) and only a few PI-stained bacteria (red) were observed in both control (PBS; Fig. 4a) and Sc-NK2A (Fig. 4b) treated samples, indicating that Sc-NK2A did not have detectable antimicrobial activity. In contrast, many dead (red) Salmonella SX238 were detected in NK2A treated samples, further confirming the growth assay findings that NK2A is bactericidal to Salmonella (Fig. 4c).

To visualize ultrastructural changes to Salmonella SX238 outer- (LPS) and inner- (cytoplasmic) membranes following incubation with NK2A, bacterial samples were evaluated using TEM. Salmonella SX238 in PBS (control, Fig. 4d) or with Sc-NK2A (Fig. 4e) were normal bacilli-shaped bacteria with intact outer- and inner-membranes and typical electron-dense cytoplasm. The periplasmic spaces in both samples were thin and uniform. These observations suggest that the bacteria were alive, and Sc-NK2A did not cause detectable damage to the bacterial membranes. In contrast, SX238 treated with NK2A had extensively damaged outer- and inner-membranes and cytosolic content leakage (Fig. 4f,g). Due to the loss of membrane integrity and cytosolic contents, the bacteria were smaller in size, lacked the typical bacilli morphology and appeared collapsed. NK2A-treated SX238 had slightly wavy inner membranes (Fig. 4f,g), wider periplasmic spaces (Fig. 4f,g and 6d) and were visibly non-uniform. Collectively, these findings suggest that NK2A disrupted both the outer- and inner-membranes of Salmonella.

Kinetics of MDR Salmonella killing by NK2A. The bacterial killing, CLSM and TEM studies suggest that the bactericidal effect of NK2A against Salmonella is membranolytic activity. To determine the kinetics of Salmonella cytosolic membrane permeabilization by NK2A, a PI uptake assay was performed. PI is a cell impermeant fluorescent dye and can only bind/intercalate with cellular DNA (and RNA) when the bacterial
Figure 2. Characterization of scrambled NK2A (Sc-NK2A) peptide. (a) Secondary structures of Sc-NK2A and NK2A were determined using circular dichroism (CD) analysis in aqueous buffer (without liposome) and bacterial membrane-mimicking environment (with liposome). Raw data in millidegrees was converted to molar ellipticity (Θ∙cm²/dmol·10⁻³). Average spectra with six accumulations after baseline correction for each of the peptides are shown. (b) Hemolytic activities of Sc-NK2A and NK2A on cattle red blood cells (RBCs) were determined spectrophotometrically (OD₄₀₅nm) by measuring released hemoglobin. Data are presented as mean ± SD of percentage of hemolysis from two animals. P=0.1650 as determined by ANOVA test using GLM procedure from SAS software, Version 9.4 of the SAS System for Windows. (c). Antimicrobial activity of Sc-NK2A (and NK2A) against *Salmonella* isolate SX238 was recorded using an automated growth curve reader. Optical density readings (OD₆₀₀nm) of different bacterial CFU (10⁴–10⁷ CFU/well; BO = bacteria only) with 10 µM peptide concentrations are shown. Representative graphs out of three independent experiments are shown.
Figure 3. Antimicrobial activity of NK2A and Sc-NK2A against *Salmonella* isolates. Three MDR *Salmonella* outbreak isolates (SX238, SX231 and SB395) and one non-MDR *Salmonella* isolate (SB377) (10⁶ CFU/mL) were incubated with different concentrations of NK2A, Sc-NK2A or Luria–Bertani broth (LB) and optical densities (OD₆₀₀nm) were recorded using an automated growth curve reader over a 24 h period. One representative graph (for each peptide and each isolate) out of at least three independent experiments is shown.
cytoplasmic membranes are compromised. With similar features as NK2A, cyclic polycationic polymyxin B was selected as a positive control for the assay because polymyxin B is a peptide and a rapid-acting bactericidal antibiotic which interacts with bacterial LPS as well as the cytoplasmic membrane. Growth curve assays with polymyxin B (2–512 µg/mL) showed that as little as 2 µg/mL was sufficient to completely inhibit Salmonella SX238 growth during the 24 h incubation (Fig. 5a). No PI uptake signal was observed with Salmonella SX238 incubated with polymyxin B at concentrations even as high as 100 µg/mL during a 30 min observation period (Fig. 5b) as well as 6 h observation period (Supplementary Fig. S2). Furthermore, Salmonella incubated with Sc-NK2A or PBS (negative control) did not show PI uptake signals (Fig. 5b), indicating that neither polymyxin B nor the scrambled NK2A peptide disrupted the cytosolic membranes. In contrast, rapid PI uptake was observed for Salmonella SX238 incubated with NK2A (5 µM), and PI fluorescent signal intensity steadily increased during the 30 min incubation period, suggesting that the bacterial cytoplasmic membrane was disrupted (or permeabilized) by NK2A (Fig. 5b).

**Table 2.** Characterization of bovine NK-lysin peptides and polyanhydride nanoparticles. NA not applicable.

| Reagent/formulation | Mean diameter (nm) | Zeta potential (mV) | Encapsulation efficiency |
|---------------------|--------------------|---------------------|-------------------------|
| NK2A                | NA                 | +24.8 ± 1.1         | NA                      |
| Sc-NK2A             | NA                 | +16.3 ± 6.2         | NA                      |
| NK1                 | NA                 | +23.5 ± 2.3         | NA                      |
| NK2B                | NA                 | +17.0 ± 1.7         | NA                      |
| NK2C                | NA                 | +17.8 ± 2.2         | NA                      |
| Empty 20:80 CPTEG:CPH | 239 ± 96         | +21.4 ± 3.5         | NA                      |
| Empty 10:90 CPTEG:SA | 334 ± 127         | −33.5 ± 1.0         | NA                      |
| Empty 20:80 CPHE:SA | 341 ± 139         | −29.8 ± 0.9         | NA                      |
| 20:80 CPTEG:CPH 5% NK2A | 243 ± 97         | +20.7 ± 2.9         | 34.3%                   |
| 20:80 CPTEG:CPH 5% kanamycin | 285 ± 91        | +39.8 ± 4.4         | 42.1%                   |
| 10:90 CPTEG:SA 10% NK2A | 367 ± 156        | +37.2 ± 2.5         | 47.3%                   |
| 20:80 CPHE:SA 10% NK2A | 641 ± 150        | +39.5 ± 3.0         | 38.9%                   |

**Table 3.** Zeta potential of MDR and non-MDR Salmonella outbreak isolates before and after 2 µM NK2A and Sc-NK2A treatments for 20 min. NT not tested.

|          | SX238 | SX231 | SB377 | SB395 |
|----------|-------|-------|-------|-------|
| H2O/PBS  | −2.8 ± 0.7 mV | −6.3 ± 2.1 mV | −9.0 ± 3.1 mV | −4.0 ± 1.7 mV |
| NK2A     | +16.0 ± 1.5 mV | +15.8 ± 1.2 mV | +13.3 ± 1.9 mV | +6.1 ± 2.7 mV |
| Sc-NK2A  | NT     | NT     | NT     | +7.8 ± 1.4 mV |

Binding of NK2A with Salmonella LPS. To visualize NK2A binding to Salmonella LPS and assess concordant NK2A-induced Salmonella growth inhibition, a bacterial growth curve assay was performed following preincubation of NK2A (5 µM or 2.2 µg) with increasing LPS concentrations (0, 1.1, 2.2, 4.4 and 8.8 µg). As previously shown (Fig. 1 and 3), 5 µM NK2A was able to completely inhibit the growth of Salmonella SX238 during 24 h incubation (Fig. 6a). Preincubation of 5 µM NK2A with 1.1 µg and 2.2 µg LPS showed delayed bacterial growth recovery (~5–10 h), while LPS at 4.4 µg and 8.8 µg completely inhibited the antimicrobial activity of NK2A on Salmonella SX238 (Fig. 6a). These findings suggest that NK2A irreversibly binds to LPS.

To confirm this binding, Salmonella SX238 was incubated with NK2A conjugated with gold nanoparticles (NK2A-AuNP) (10 nm diameter) or control AuNPs (without NK2A) and investigated for particle-LPS localization and membrane integrity by TEM. No AuNP localization with Salmonella SX238 membranes were observed in AuNP control samples (Fig. 6b). By contrast, NK2A-AuNPs produced numerous Salmonella membrane localization sites (Fig. 6c). Most of the NK2A-AuNPs were bound to Salmonella outer membrane or LPS (Fig. 6c–e; black arrows), while fewer NK2A-AuNPs bound to the inner cytoplasmic membranes (Fig. 6e, white arrows). Bacteria with damaged outer LPS (Fig. 6d, black triangles) and inner cytoplasmic membranes were observed (Fig. 6d, white triangles), and these bacterial cells had expanded periplasmic spaces (Fig. 6d), presumably due to NK2A-mediated rupture of the inner cytoplasmic membrane.

Characterization of nanoparticles. To test the compatibility of NK2A with polymeric nano-carrier delivery devices, a small library of polyhynidride nanoparticle formulations was synthesized. Empty 20:80 CPTEG:CPH, 10:90 CPTEG:SA, and 20:80 CPHE:SA nanoparticle formulations had mean diameters of ~239–341 nm (Table 2). NK2A-loaded formulations had similar size distributions to the corresponding empty formulations (Table 2). Morphologically, the CPTEG:SA and CPHE:SA nanoparticles tended to be spherical and less aggregated, while the CPTEG:CPH nanoparticles tended to be less spherical and slightly more aggregated when visualized by SEM (Fig. 7a).
Payload type dramatically affected nanoparticle release kinetics in PBS, pH 7.4. Kanamycin-loaded nanoparticles showed a burst-dominated release profile, with approximately 90% release within 1 day and little drug released over the following 6 days (Fig. 7b). This result could indicate poor compatibility of the relatively
hydrophilic drug within the hydrophobic polyanhydride polymer matrix, resulting in kanamycin localization at the particle surface. By contrast, NK2A formulations showed a slow, sustained release, releasing < 35% of their payload over 1 week (Fig. 7b). This slow release is likely a result of the hydrophobicity of the NK2A peptide enabling better mixing with the polymer within the nanoparticles. This correlates with a more homogeneous distribution of NK2A within the particles, allowing polymer degradation and surface erosion to control release. All NK2A- and kanamycin-loaded nanoparticles showed moderate encapsulation efficiencies between 34.3 and 47.3%.

Each empty nanoparticle chemistry showed negative Zeta potential values, attributable to dicarboxylic acid residues that are produced at the surface after hydrolysis of the anhydride bond37 (Table 2). However, NK2A encapsulation produced a profound, sign-inverting increase in observed Zeta potentials, likely due to the cationic nature of the NK2A peptide (Table 2).

Antimicrobial activity of NK2A nanoparticles. To assess the antimicrobial activity of NK2A nanoparticles, MDR Salmonella SX238 (10^9 CFU/ml) was incubated (3 h) with NK2A nanoparticles (5 µM final concentration). Efficient Salmonella SX238 killing was observed with 20:80 CPTEG:CPH kan nanoparticles (final kanamycin concentration = 16 µg/mL) (Fig. 7c). Both 10:90 CPTEG:SA and 20:80 CPH:SA NK2A-loaded nanoparticles showed 100% Salmonella SX238 killing, while 20:80 CPTEG:CPH NK2A-loaded nanoparticles exhibited ~ 80%
SX238 killing (Fig. 7c) (*P<0.0001). This differential Salmonella SX238 killing could indicate polymer chemistry interactions with the NK2A peptide, affecting its capacity to localize at the bacterial surface, or alternatively polymer-bacteria interactions. These considerations should be explored further in future research.

**Discussion**

*Salmonella* is a major causative agent of bacterial foodborne illness in the U.S.\(^3\),\(^38\). In a 2019 United States antibiotic resistance threats report, the CDC classified both drug resistant nontyphoidal and typhoidal *Salmonella* as serious threats to global health\(^2\). Approximately 10% of *Salmonella* are multidrug-resistant with a few of the isolates defined as extremely resistant (resistant to eight or more antimicrobial classes\(^39\)); thus, innovative non-antibiotic strategies are needed to limit *Salmonella* colonization of food animals and contamination of their food products\(^40\). Despite the availability of over 19,000 antimicrobial agents\(^41\), the literature on MDR *Salmonella*...
susceptibility to AMPs is notably sparse\textsuperscript{42}. AMPs are ideal molecules to test against MDR Salmonella because AMPs generally induce rapid bacterial killing, have a broad spectrum of antimicrobial activity, and have a reduced proclivity for cultivating bacterial resistance compared to classical antibiotics\textsuperscript{10}. It has previously been reported that 30-mer peptides derived from bovine NK-lysins are potent inhibitors against a variety of bacteria\textsuperscript{17,20,21,23–25}. This study established NK2A and NK2B as highly effective against Salmonella isolates (MDR and non-MDR). Both peptides were able to inhibit the growth of Salmonella at low micromolar concentrations (3.5–5 µM) during a 24 h incubation in LB broth (Fig. 1a). Although certain AMPs show reduced antimicrobial activity in the presence of salt\textsuperscript{12,13,43,44}, NK2A and NK2B were highly effective in both LB broth and PBS containing physiological concentrations of salt (NaCl ~ 100–150 mM).

Figure 7. Characterization and killing efficacy of polyanhydride nanoparticles. (a) SEM micrographs of NK2A and kanamycin loaded polyanhydride nanoparticles. (b) Nanoparticle release kinetics of NK2A and kanamycin in PBS, pH 7.4 were determined by microBCA assay or o-pthalaldehyde derivatization followed by spectroscopy, respectively. (c) Salmonella outbreak isolate SX238 was incubated with NK2A (final concentration = ~ 5 µM), kanamycin (kan; final concentration = ~ 16 µg/mL) nanoparticles, or empty nanoparticles (negative control) for 3 h. Samples were serially diluted in LB broth, plated on to XLT plates, and bacterial colonies were enumerated after overnight incubation. Percentages of bacterial killing are presented as mean ± SD from three independent experiments. Bars with no common letters (a and b) differ significantly ($P<0.0001$) as determined by ANOVA test using GLM procedure from SAS software, Version 9.4 of the SAS System for Windows.
The antimicrobial activity of cationic AMPs is predicted to be due to nonspecific interaction with bacterial membranes. Bovine NK-lysin peptides are cationic α-helical AMPs and are expected to electrostatically interact with negatively charged bacterial membranes, resulting in pore formation, intracellular content leakage and bacterial death. The net positive charges of bovine NK-lysin peptides in physiological buffer (PBS) is predicted to be $+5.0$ to $+7.9$. In general, bacterial surface charge or Zeta potential is negative due to the presence of negatively charged lipopolysaccharides in Gram negative bacteria and teichoic acids in Gram positive bacteria. Due to the complex nature of Gram negative bacterial LPS molecules, interactions of AMPs and LPS are poorly understood. Phosphatidylethanolamine, phosphatidylglycerol and cardiolipin are the major lipid components of bacterial cytoplasmic membranes among which the latter two are negatively charged. Using a Zetasizer, it was confirmed that NK-lysin peptides have net positive Zeta potentials while *Salmonella* isolates have net negative Zeta potentials (Tables 2–3). Incubation of *Salmonella* isolates with NK2A resulted in increased bacterial Zeta potentials, suggesting electrostatic interaction and charge neutralization between NK2A and bacterial LPS and cytoplasmic membrane. Some studies suggested that increased Zeta potentials can be used as a potential marker to assess damage to bacterial membranes or viability. However, increased Zeta potentials of *Salmonella* (isolate SB395) were observed even with Sc-NK2A which has minimal bacterial killing activity. Therefore, the findings suggest that increased bacterial Zeta potential alone is an imperfect tool for assessing AMP-mediated membrane permeabilization of *Salmonella* isolates.

Although direct bovine NK-lysin peptide binding to bacterial membranes has not been demonstrated, the increase in Zeta potential of *Salmonella* with NK2A in this study suggested NK2A-membrane interactions. Membranolytic activity of NK2A is supported by our experimental findings from live/dead bacterial viability staining, PI uptake assay, and TEM. Moreover, two specific experiments were conducted to confirm NK2A binding with MDR *Salmonella* SX238 membranes. Preincubation of NK2A with increasing concentrations of *Salmonella* LPS prevented NK2A-mediated inhibition of growth (Fig. 6a). This suggests that NK2A-LPS binding is irreversible. TEM detection of NK2A-AuNP conjugates on both bacterial outer- and inner-membranes confirmed direct binding of NK2A to MDR *Salmonella* SX238 LPS and the cytoplasmic membrane.

Our ultimate goal is to develop non-antibiotic strategies to control *Salmonella* colonization and shedding in food animals. Of the four bovine NK-lysin peptides tested in this study, NK2A appeared to be the best candidate. In general, AMPs show poor pharmacokinetic properties because of their small size, hydrophobicity, and sensitivity to proteolytic degradation. Polyanhydride nanoparticles have been extensively characterized as a delivery platform for small molecules (including antimicrobials) and biomolecules. Polyanhydride nanoparticles entrap and protect sensitive payloads from harsh physiological environments (like proteases and low pH), traffic the payload to the site of action, and control the release of the payload. These features could improve peptide stability, enhance AMP bioavailability, reduce proteolytic degradation, and decrease treatment frequency. In vitro release kinetics assays revealed that all tested nanoparticle formulations produced slow and sustained release of NK2A. These nanoparticle formulations also preserved NK2A functional activity, given that ~80% (in the case of 20:80 CPTEG:CPH particles) to 100% (for 10:90 CPTEG:SA and 20:80 CPH:SA particles) MDR *Salmonella* killing was observed. These findings suggest that polyanhydride nanoparticles have the features of a suitable nano-carrier delivery platform for NK2A, and merit further investigation in future animal trials.

In conclusion, this study revealed that among four bovine NK-lysin peptides, NK2A and NK2B showed potent antimicrobial activity against *Salmonella* isolates (MDR and non-MDR). Using a variety of techniques, it was demonstrated that NK2A directly and irreversibly binds to bacterial LPS and the cytoplasmic membrane, leading to membrane permeability, intracellular content leakage, and bacterial death. Initial investigation of NK2A-loaded polyanhydride nanoparticles indicates both sustained release and peptide protection capabilities, motivating further exploration of a nano-carrier delivery approach for NK-lysin-based therapies to treat MDR *Salmonella* infections. Such an innovative, non-antibiotic strategy could aid efforts to control the spread of MDR *Salmonella* infections in animal and human populations.

### Materials and methods

**Peptide synthesis.** Thirty-mer peptides corresponding to the functional region helices 2-loop-3 of bovine NK-lysins (NK1: VIIVHTSVKCSMKGLWSILCNQMMKKYLNR, net charge = $+5.0$; NK2A: TVIEVASKMC-SKMRILKGLCKSKITKRFLRR, net charge = $+7.9$; NK2B: TVIEAASKVCMGPKLGLCKSKITKRFLRR, net charge = $+6.9$; NK2C: TVIEAEKSVKSMRLLKGKLMKMKSFLRT, net charge = $+5.9$ and a scrambled version of NK2A (Sc-NK2A): MFVSLATILTGKSKCKCERMKLRRV, net charge = $+7.9$) were synthesized by Peptide 2.0 Inc., Chantilly, VA. Lyophilized peptides were dissolved in Dulbecco’s phosphate-buffered saline (PBS, pH 7.2), aliquoted, and stored at $-20 ^\circ C$ until used.

**Peptide concentration determination.** Concentrations of all NK-lysin peptides and Sc-NK2A were determined by quantitative amino acid analysis at the Protein Chemistry Laboratory, Texas A&M University and the Center for Biotechnology, University of Nebraska-Lincoln.

**Animals and ethics.** The authors complied with the ARRIVE guidelines. All animal procedures were conducted in strict accordance with the Animal Welfare Act, and all procedures were approved by the Institutional Animal Care and Use Committee at the National Animal Disease Center, Ames, IA. Blood samples collected from 4 years old healthy two Holstein cows from National Animal Disease Center were used to isolate red blood cells.
Mouse study. To determine whether NK-lysin peptides show in vivo cytotoxic effects, a mouse study was conducted. Briefly, thirty 5–6 weeks old female Swiss-Webster mice (Envigo, Indianapolis, IN) were housed in groups in six individual cages (5 mice per cage) in ABSL2 facilities with ad libitum access to food and water in a 12-h light:dark cycle. After 1 week of acclimation, mice were intraperitoneally injected with a single dose of 100 µg of NK-lysin peptides (NK1, NK2A, NK2B, NK2C, or Sc-NK2A, ~ 4 mg/kg of body weight) in PBS (1 mL). Mice injected with PBS (1 mL) served as a negative control for the study. Mice were daily observed for any signs of toxicity and were euthanized 2 weeks post peptide administration.

Circular dichroism (CD) analysis. CD analysis of all four bovine NK-lysin peptides were previously described24. Therefore, CD analyses were performed here using the same methods for NK2A and Sc-NK2A in potassium phosphate buffer and liposomes using Jasco J-815 CD spectrophotometer (Jasco, Easton, MA).

Hemolytic activity assay. The hemolytic activity of all four bovine NK-lysin peptides, as the amount of hemoglobin released by the lysis of cattle red blood cells (RBCs), were previously determined20. Therefore, only hemolytic activity of Sc-NK2A was compared with NK2A (final concentrations for both peptides at 2, 5, 10, and 20 µM) using cattle RBCs in this study as described previously20. Triton X-100 and PBS were used as positive and negative control for the assay, respectively.

Nanoparticle synthesis. SA monomer was purchased from Sigma Aldrich (St. Louis, MO). CPH and CPTEG monomers were synthesized as previously described52,53. The 20:80 CPTEG:CPH, 20:80 CPH:SA, and 10:90 CPTEG:SA copolymers were synthesized by melt condensation to number average molecular weights of approximately 7.5, 17.5, and 17.5 kDa, respectively49,52–54, and composition and molecular weight were confirmed by 1H NMR analysis using a Varian MR-400 (Varian, Inc., Palo Alto, CA). Nanoparticles were synthesized by flash nanoprecipitation26. Nanoparticles were collected by vacuum filtration, scanning electron microscopy (SEM, FEI Quanta 250, Hillsboro, OR) was used to image all formulations, and size distributions were calculated using Fiji image analysis software55. Nanoparticle Zeta potential was measured (see below) using a Zetasizer Nano (Malvern Instruments Ltd., Worcester, UK).

Nanoparticle release kinetics. Nanoparticle release kinetics and encapsulation efficiency were assayed in PBS, pH 7.4 as previously described29,30. Released NK2A peptide concentrations were quantified by micro bicinechonic acid (microBCA) assay (Pierce Biotechnology, Rockford, IL). Kanamycin was quantified by o-phthalaldehyde derivatization56 (Fluoraldhehyde crystals, ThermoFisher Scientific, Carlsbad, CA) followed by absorbance spectroscopy at 340 nm (SpectraMax M3, Molecular Devices, San Jose, CA). Drug release kinetics are presented as fraction released, where the cumulative payload mass released is normalized by the total encapsulated payload mass.

MDR Salmonella isolates and culture conditions. MDR Salmonella outbreak isolates (SX238, SX231, and SB395) as well as a non-MDR Salmonella isolate (SB377) used in this study are listed in Table 1. Bacterial freezer stocks were streaked individually onto Luria–Bertani (LB) Lennox agar (Sigma Aldrich) and incubated in a 37 °C incubator overnight. Bacterial cultures were prepared by growing each isolate from a single colony in 3 mL LB Lennox broth (ThermoFisher Scientific, Wilmington, DE) overnight at 37 °C in a shaker-incubator at 200 rpm.

MDR Salmonella-NK-lysin peptide susceptibility assays. Overnight cultures of a MDR Salmonella outbreak isolate (SX238) and one non-MDR Salmonella isolate (SB377) were diluted 1:1000 in LB broth to obtain approximately 1 × 10⁶ colony forming units per milliliter (CFU/mL). One hundred microliters of each diluted culture were transferred into honeycomb® 100-well plates (~ 1 × 10⁵ CFU/well) (Growth Curves USA, Piscataway, NJ). Bovine NK-lysin peptides (NK1, NK2A, NK2B, and NK2C) were added at the final peptide concentrations of 20, 10, 5, 3.5, 2 µM in PBS (total volume = 20 µL) with a final bacterial-peptide volume of 120 µL/well. The plates were covered with lids and placed in an automated growth curve reader (Bioscreen C; Growth Curves USA, Piscataway, NJ) which was programmed for continuous shaking at 37 °C, and optical density readings at 600 nm (OD₆₀₀) were recorded every hour for 24 h. Bacteria incubated with kanamycin and PBS were used as positive and negative control for the assay, respectively. The optical density data were analyzed, and growth curve graphs for each isolate were generated using MS Excel. Because NK2A peptide showed the strongest Salmonella growth inhibition, this peptide was selected for further studies. Twenty-four-hour growth curve assays for Salmonella isolate SX238 were repeated at different bacterial CFU (~ 1 × 10⁸, 1 × 10⁷, 1 × 10⁶, and 1 × 10⁵ CFU/mL) with NK2A (5 µM and 10 µM). Sc-NK2A was included as a control for the assay.

The bactericidal effect of NK2A peptide against MDR Salmonella (SX238) was also determined. Overnight SX238 culture was centrifuged (10,000 rpm for 2 min) and diluted 1:1000 in LB broth and/or PBS to obtain ~ 1 × 10⁶ CFU/mL. 100 µL of diluted bacterial culture was placed in a Honeycomb plate (~ 1 × 10⁶ CFU/well). NK2A (20, 5, 2, and 0 µM) was added and incubated at 37 °C in the reader with continuous shaking for 3 h. Bacteria in each well was 10× serially diluted in LB broth, 10 µL was plated on Xylose-Lysine-Tergitol 4 (XLT4) (ThermoFisher) agar plates and incubated at 37 °C overnight. Bacterial colonies were enumerated for each NK2A dilution.

Antimicrobial activity of NK2A (final concentration ~ 5 µM) encapsulated nanoparticles (CPTEG:CPH, CPH:SA and CPTEG:SA) were tested against Salmonella isolate SX238 as previously described25. To prepare 10 µM NK2A stock solutions, required amounts of nanoparticles was measured, added into 1 mL PBS and briefly
sonicated as previously described\textsuperscript{32}. One hundred microliters of NK2A nanoparticles and 100 µL of diluted bacterial culture in PBS was added into a Honeycomb plate (~1 × 10⁵ CFU/well) and incubated at 37 °C in the reader with continuous shaking for 3 h. Bacteria in each well was 10× serially diluted in LB broth, 10 µL was plated on XLT4 agar plates and incubated at 37 °C overnight. Kanamycin (final concentration = 16 µg/mL) encapsulated and empty nanoparticles were used as positive and negative control for the assay, respectively. Bacterial colonies were enumerated for each nanoparticle treatment.

The percentage of bacterial killing was calculated using the following Eq. (1 − [average number of live bacteria in NK2A-treated sample/average number of live bacteria in the negative control sample] × 100). The antimicrobial assays for 	extit{Salmonella} isolates were repeated at least three times in duplicate wells.

**Zeta potential measurements.** 	extit{Salmonella} isolates were prepared for Zeta potential measurements via the diffusion barrier technique as previously described but with some minor modifications\textsuperscript{35}. Briefly, overnight cultures of 	extit{Salmonella} in LB broth were centrifuged (10,000 rpm for 2 min), washed twice in Milli-Q water and resuspended in Milli-Q water (~1 × 10⁶ CFU/mL). Bacteria were then diluted 1:1000 in Milli-Q water supplemented with 10% PBS, then transferred to clear disposable folded capillary Zeta cells filled with 10% PBS via gel loading pipette tip (Malvern Instruments Ltd). The Zeta potential measurements (mV) of bacterial isolates were immediately measured using a Zeta potential analyzer equipped with He–Ne 633 nm laser (Zetasizer Nano, Malvern) at a constant voltage of 150 V at room temperature. The Zeta potential changes of 	extit{Salmonella} isolates following incubation with NK2A were also recorded. Bacterial isolates (~10⁶ CFU in 1 mL Milli-Q water) were incubated with 2 µM NK2A (in PBS) at 37 °C for 20 min. Capillary Zeta cells were washed with Milli-Q water between samples and refilled with Milli-Q water containing 10% PBS before measuring the Zeta potentials. Zeta potential changes of one 	extit{Salmonella} isolate (SB395) was also similarly tested with Sc-NK2A (2 µM) peptide. This method was also used for assessing NK-lys in peptide Zeta potentials. A total of five Zeta potential measurements of 40 runs each with 30 s cooling cycles for each sample was performed.

**Confocal laser scanning microscopy (CLSM).** The viabilities of bacteria following incubation with NK2A and Sc-NK2A were determined using culture-independent (function of the membrane integrity of the bacteria) staining technique by using LIVE/DEAD™ BacLight™ bacterial viability kit (for microscopy) as described previously\textsuperscript{36}. Bacteria in each treatment was visualized using a Nikon A1R + laser scanning confocal microscope (Nikon Instruments, Melville, NY) as described previously\textsuperscript{20}. Images were obtained using plan Apo 60× objective lens (oil) at numerical aperture 1.4. Final figures were prepared using Adobe Photoshop Elements 11.

**Transmission electron microscopy (TEM).** Morphological changes of bacteria following incubation with NK2A and Sc-NK2A peptides were studied by TEM. An overnight culture of 	extit{Salmonella} isolate SX238 was centrifuged and resuspended in PBS. One hundred microliters of bacterial suspension were placed in a Honeycomb plate (~1 × 10⁷ CFU/well) and NK2A, Sc-NK2A (20 µM), and PBS were added and incubated at 37 °C with continuous shaking for 1 h. The bacterial suspensions were mixed with an equal volume of 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and processed for TEM as described before\textsuperscript{34}. Sections were examined with a FEI Tecnai G2 Biotwin (FEI Co., Hillboro, OR) TEM and images were taken with Advanced Microscopy Technologies (AMT Inc., Danvers, MN) imaging camera.

**Propidium iodide (PI) uptake assay.** The kinetics of NK2A-induced damage to 	extit{Salmonella} cell membranes were evaluated using PI uptake assay as described previously\textsuperscript{24}. Briefly, an overnight culture of MDR 	extit{Salmonella} outbreak isolate SX238 was centrifuged, washed with PBS, and resuspended in PBS. Ninety microliters of bacterial suspension was transferred to a 96-well opaque plate (~1 × 10⁷ CFU/well) and NK2A, Sc-NK2A (20 µM), and PBS were added and incubated at 37 °C with continuous shaking for 1 h. The bacterial suspensions were mixed with an equal volume of 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and processed for TEM as described before\textsuperscript{34}. Sections were examined with a FEI Tecnai G2 Biotwin (FEI Co., Hillboro, OR) TEM and images were taken with Advanced Microscopy Technologies (AMT Inc., Danvers, MN) imaging camera.

**NK2A-Lipopolysaccharides (LPS) binding studies.** The binding of NK2A to 	extit{Salmonella} LPS was studied by growth curve assay and TEM. Five micromolar NK2A (~2.2 µg/well) was preincubated with different amounts of 	extit{Salmonella enterica} serotype Typhimurium LPS (Sigma; LPS = 0, 0.5, 1.1, 2.2, 4.4, 8.8 µg/well, final volume of LPS and NK2A = 20 µL) at 37 °C in a honeycomb plate with continuous shaking for 30 min. Overnight 	extit{Salmonella} (isolate SX238) culture was diluted to ~1 × 10⁶ CFU/mL and 100 µL was transferred into wells containing NK2A-LPS and further incubated at 37 °C with continuous shaking for 24 h. The optical density (OD₅₃₀) data were analyzed, and growth curve graphs were generated.

The direct binding of NK2A to 	extit{Salmonella} LPS/membranes was also examined by TEM using gold nanoparticle-conjugated NK2A (NK2A-AuNPs). Ten nanometer (diameter) NHS-activated gold nanoparticles (AuNPs) were conjugated to NK2A as described by the manufacturer (Cytodiagnostics Inc., Burlington, ON, Canada). One hundred microliters of 	extit{Salmonella} isolate SX238 was placed in a Honeycomb plate (~1 × 10⁸ CFU/well) and incubated with NK2A-AuNPs (20 µM) or AuNPs (without NK2A) at 37 °C with continuous shaking for 15–45 min. Bacterial samples were fixed with 3% glutaraldehyde and processed for TEM as described above.
**Statistical analyses.**  The data analysis for this paper was generated using SAS® software, Version 9.4 of the SAS System for Windows. Copyright © 2002–2012. SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. When significant, mean comparisons were performed using the predicted differences (PDIFF) option. Significant differences were established at P ≤ 0.05.

**Data availability**

All the data supporting the conclusions have been included within the article.

Received: 25 May 2021; Accepted: 14 September 2021

Published online: 29 September 2021

**References**

1. Centers for Disease Control and Prevention, N. C. F. E. a. Z. I. D., Division of Foodborne, Waterborne, and Environmental Diseases. 25March2020 Available from https://www.cdc.gov/salmonella/index.html.

2. https://www.cdc.gov/drugresistances/biggest-threats.html, C. A. t. i. t. U. S.

3. www.cdc.gov/salmonella/outbreaks.html.

4. Brott, D. et al. Nationwide outbreak of multidrug-resistant Salmonella Heidelberg infections associated with ground turkey: United States, 2011. Epidemiol. Infect. 143, 3227–3234. https://doi.org/10.1017/S0950268815000497 (2015).

5. Kawakami, V. M. et al. Notes from the field: outbreak of multidrug-resistant salmonella infections linked to pork-Washington, 2015. MMWR Morb. Mortal Wkly. Rep. 65, 379–381. https://doi.org/10.15585/mmwr.mm6514a4 (2016).

6. Laxminarayan, R. et al. Antibiotic resistance—the need for global solutions. Lancet Infect. Dis. 13, 1057–1098. https://doi.org/10.1016/S1473-3099(13)70318-9 (2013).

7. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 3, 238–250. https://doi.org/10.1038/nrmicro1098 (2005).

8. Mahlapuu, M., Hakansson, J., Ringstad, L. & Bjorn, C. Antimicrobial Peptides: an emerging category of therapeutic agents. Front. Cell Infect. Microbiol. 6, 194. https://doi.org/10.3389/fcimb.2016.00194 (2016).

9. Bahar, A. A. & Ren, D. Salmonella. Pharmaceuticals (Basel) 16, 1543–1575. https://doi.org/10.3390/ph16121543 (2013).

10. Divyashree, M. et al. Clinical applications of antimicrobial peptides (AMPs): where do we stand now?. Protein Pept. Lett. 27, 120–134. https://doi.org/10.2174/0929866562666190925152957 (2020).

11. Sierra, J. M., Fuste, E., Rabanal, F. & Vinas, M. An overview of antimicrobial peptides and the latest advances in their development. Expert Opin. Biol. Ther. 17, 663–676. https://doi.org/10.1080/14712598.2017.1315402 (2017).

12. Bovdsh, D. M. et al. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77, 451–459. https://doi.org/10.1189/jlb.0704305 (2005).

13. Kim, W. H., Lillehoj, H. S. & Min, W. Evaluation of the immunomodulatory activity of the chicken NK-lysin-derived peptide cNK-2. Sci. Rep. 7, 45099. https://doi.org/10.1038/srep45099 (2017).

14. Andersson, M. et al. NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumour activity. EMBO J. 14, 1615–1625 (1995).

15. Andreu, D., Carreno, C., Linde, C., Boman, H. G. & Andersson, M. Identification of an anti-mycobacterial domain in NK-lysin and granulysin. Biochim. Biophys. Acta 1744 (Pt 3), 845–849 (1999).

16. Stenger, S. et al. An antimicrobial activity of cytotoxic T cells mediated by granulysin. Science 282, 121–125. https://doi.org/10.1126/science.282.5386.121 (1998).

17. Endley, J. J. et al. Characterization of bovine homologues of granulysin and NK-lysin. J. Immunol. 173, 2607–2614. https://doi.org/10.4049/jimmunol.173.4.2607 (2004).

18. Pena, S. V., Hansom, D. A., Carr, B. A., Goralski, T. J. & Krensky, A. M. Processing, subcellular localization, and function of 519. melano-melanocytes. J. Biol. Chem. 278, 1123–1126 (2003).

19. Munford, R. S., Sheppard, P. O. & O’Hara, P. J. Saposin-like proteins (SAPLIP) carry out diverse functions on a common backbone structure. J. Lipid Res. 36, 1653–1663 (1995).

20. Dassanayake, R. P., Falkenberg, S. M., Briggs, R. E., Tatum, F. M. & Sacco, R. E. Antimicrobial activity of bovine NK-lysin-derived peptides on bovine respiratory pathogen Histophilus somni. PLoS ONE 12, e0183610. https://doi.org/10.1371/journal.pone.0183610 (2017).

21. Chen, J. et al. Bovine NK-lysin: Copy number variation and functional diversification. Proc. Natl. Acad. Sci. USA 112, E7223–E7229. https://doi.org/10.1073/pnas.1519374113 (2015).

22. Andersson, M. et al. NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Vet. Immunol. Immunopathol. 54, 123–126. https://doi.org/10.1016/j.vetim.2005.06.077 (2006).

23. Chen, J. et al. Expression of the Bovine NK-Lysin Gene Family and Activity against Respiratory Pathogens. PLoS ONE 11, e0158882. https://doi.org/10.1371/journal.pone.0158882 (2016).

24. Dassanayake, R. P. et al. Antimicrobial activity of bovine NK-lysin-derived peptides on Mycoplasma bovis. PLoS ONE 13, e0197677. https://doi.org/10.1371/journal.pone.0197677 (2018).

25. Dassanayake, R. P. et al. Bovine NK-lysin-derived peptides have bactericidal effects against Mycobacterium avium subsp.paratuberculosis. Vet. Res. 52, 11. https://doi.org/10.1186/s13567-021-00889-3 (2021).

26. Mullis, A. S., Peroutka-Bigus, N., Phadke, K. S., Belloire, B. H. & Narasimhan, B. Nanomedicines to counter microbial barriers and antimicrobial resistance. Curr. Opin. Chem. Eng. 31, 100672 (2021).

27. Mullis, A. S., Schlichtmann, B. W., Narasimhan, B., Cademartiri, R. & Mallapragada, S. K. Ligand-cascading nano-delivery devices to enable multiscale targeting of anti-neurodegenerative therapeutics. Biomol. Mater. 13, 034102. https://doi.org/10.1088/1748-605X/aaaa778 (2018).

28. Ross, K. A. et al. Nano-enabled delivery of diverse payloads across complex biological barriers. J. Control Release 219, 548–559. https://doi.org/10.1016/j.jconrel.2015.08.039 (2015).

29. Mullis, A. S. et al. Data analytics approach for rational design of nanomedicines with programmable drug release. Mol. Pharm. 16, 1917–1928. https://doi.org/10.1021/acs.molpharmaceut.8b01272 (2019).

30. Mullis, A. S., Jacobson, S. J. & Narasimhan, B. High-throughput synthesis and screening of rapidly degrading polyanhydride nanoparticles. ACS Comb. Sci. 22, 172–183. https://doi.org/10.1021/acsbsci.b900162z (2020).

31. Torres, M. P., Vogel, B. M., Narasimhan, B. & Mallapragada, S. K. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms. J. Biomed. Mater. Res. A 76, 102–110. https://doi.org/10.1002/jbm.a.30510 (2006).

32. Lueth, P. et al. Nanotherapeutic provides dose sparing and improved antimicrobial activity against Brucella melitensis infections. J. Control Release 294, 288–297. https://doi.org/10.1016/j.jconrel.2018.12.024 (2019).
A.M., E.N. and S.F. performed experiments and R.D., B.A., A.M., E.N., S.F., B.N., E.C. and S.B. analysed and interpreted the data. R.D., B.A., A.M., B.N. and S.B. wrote the manuscript. All authors reviewed the manuscript.

Acknowledgements

The authors would like to thank Judith Stasko, Adrienne Shircliff, Tracy Porter, and Duane Zimmerman at the National Animal Disease Center for their excellent technical support. A.M. and B.N. were supported by the Iowa State University Nanovaccine Institute. B.N. also acknowledges the Vlasta Klima Balloun faculty chair for support.

Author contributions

R.D. and S.B conceived and supervised the project. R.D., B.A., E.C., B.N. and S.B designed the study. R.D., B.A., A.M., E.N. and S.F. performed experiments and R.D., B.A., A.M., E.N., S.F., B.N., E.C. and S.B. analysed and interpreted the data. R.D., B.A., A.M., B.N. and S.B wrote the manuscript. All authors reviewed the manuscript.
Funding
This research was conducted at a U.S. Department of Agriculture (USDA) research facility. This research was supported by funding through internal USDA research dollars (USDA/Agricultural Research Service, National Animal Disease Center, 5030–32000-116-00D and 5030–32000-113-00D), 2020 USDA-ARS Antimicrobial Resistance Funding (No. 0426572) and USDA-ARS Alternatives to Antibiotics Funding (No. 0426570). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Mention of trade names or commercial products in this article is solely for the purpose of providing specific information and does not imply recommendations or endorsement by the U.S. Department of Agriculture. USDA is an equal opportunity provider and employer.

Competing interests
B.N. is a co-founder of ImmunoNanoMed Inc., a start-up with business interests in the development of nano-based vaccines against infectious diseases. The other authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98860-6.

Correspondence and requests for materials should be addressed to R.P.D. or S.M.D.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021